ProQR Therapeutics (PRQR) Enterprise Value (2021 - 2025)

ProQR Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$159.7 million for Q4 2024.

  • For Q4 2024, Enterprise Value fell 24.77% year-over-year to -$159.7 million; the TTM value through Dec 2024 reached -$159.7 million, down 24.77%, while the annual FY2024 figure was -$161.7 million, 25.7% down from the prior year.
  • Enterprise Value for Q4 2024 was -$159.7 million at ProQR Therapeutics, down from -$128.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$96.7 million in Q4 2022 and bottomed at -$214.5 million in Q4 2021.
  • The 4-year median for Enterprise Value is -$143.8 million (2024), against an average of -$149.7 million.
  • The largest annual shift saw Enterprise Value soared 54.93% in 2022 before it plummeted 32.33% in 2023.
  • A 4-year view of Enterprise Value shows it stood at -$214.5 million in 2021, then skyrocketed by 54.93% to -$96.7 million in 2022, then crashed by 32.33% to -$128.0 million in 2023, then dropped by 24.77% to -$159.7 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Enterprise Value are -$159.7 million (Q4 2024), -$128.0 million (Q4 2023), and -$96.7 million (Q4 2022).